24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
12:15
"Only when women see themselves as decision makers of the future, will their situation change”
10:45
"Investments in Israel have all but disappeared - also because of the judicial coup”
08:20
Israeli startup is aiming to transform how cardiovascular disease is diagnosed and treated
08:10
Innoviz CEO: "We are a critical element in the automotive industry's revolution"
More stories
Buzz
Most popular
Daily
Weekly
1
Check Point tells employees no raises in 2023
2
eToro value plummets, raises $250 million at $3.5 valuation
3
High-tech job market in crisis, isn't expected to rebound soon
4
TripleW raises $16.5 million Series B to produce lactic acid and bioplastic from food waste
5
Israeli startup raises $11 million to use generative AI to help developers test their code
More news
Pharma
20 stories about Pharma
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
29.04.18
|
Racheli Bindman
Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April
Israeli Cannabis Device Developer Kanabo to Set Up Marijuana Farm in Europe
27.04.18
|
Tofi Stoler
To carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics
Israeli Pharmacies To Begin Selling Medical Marijuana Products
09.04.18
|
Sefi Krupsky
On April 20, selected Israeli pharmacies will begin selling prescription cannabis products as part of a pilot program for the regulation of medical marijuana sales in Israel
Teva Executive Calls Company’s Fourth Quarter “Fairly Good”
11.02.18
|
Dror Reich
Following the publication of the company's reports, S&P Global downgraded Teva’s corporate credit rating to junk bonds
Censa Pharmaceuticals Signs Joint Development Agreement with Biotech Company Retrophin
07.01.18
|
Lilach Baumer
Censa, a company developing treatments for orphan metabolic diseases, is a portfolio company of Israel-based Arkin Bio Ventures
Check Point Founder Invests in Clinical Stage Company Regenera Pharma
02.01.18
|
Dror Reich
The company intends to use the funding for a phase 3 clinical trial of its drug for sudden vision loss
The Year’s Seven Key Trends in Israeli Mergers and Acquisitions
29.12.17
|
Micki Shapira
Even without counting the Mobileye deal, 2017 was another strong year for M&A in Israel
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Employees Protest Outside Teva’s Israeli Facilities
14.12.17
|
Omer Kabir, Yoav Stoler and Keren-Or Grinberg
The demonstrations outside the company's facilities held Thursday foreshadow a full-out strike planned by the company’s employees for Sunday
Teva to Let Go 14,000 Employees Over the Next Two Years
14.12.17
|
Lilach Baumer
The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors
Israeli Pharma Company Wavelength Appoints New CEO
30.11.17
|
CTech
Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million
Teva Announces Restructuring, Ousts Second in Command
27.11.17
|
Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
With New CEO in Seat, Teva Lowers Outlook
02.11.17
|
Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
31.08.17
|
Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
Anti-Acne Drug Developer Plans Nasdaq IPO
15.08.17
|
Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
Previous Articles
More Articles
Please ensure Javascript is enabled for purposes of
website accessibility